-+ 0.00%
-+ 0.00%
-+ 0.00%

Vivani Medical Presents Phase 1 Data Showing No Treatment-Related Adverse Events With Semaglutide Implant

PUBT·11/16/2026 13:56:35
Listen to the news
Vivani Medical Presents Phase 1 Data Showing No Treatment-Related Adverse Events With Semaglutide Implant
  • Vivani Medical plans a Phase 2 dose-ranging weight-maintenance trial of its NPM-139 semaglutide implant in 2027, targeting treatment up to six months.
  • Phase 1 SLIM-1 showed no treatment-related adverse events among 10 implant recipients; five of 10 Wegovy recipients had treatment-related gastrointestinal events.
  • No serious adverse events occurred in the four-week study of 20 adults.
  • NPM-139 is designed for once- or twice-yearly dosing; Novo Nordisk's evaluation remains ongoing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.